Clinical Trials Logo

Mitochondrial Diseases clinical trials

View clinical trials related to Mitochondrial Diseases.

Filter by:
  • Active, not recruiting  
  • Page 1

NCT ID: NCT05650229 Active, not recruiting - Clinical trials for Primary Mitochondrial Disease

Efficacy of KL1333 in Adult Patients With Primary Mitochondrial Disease

FALCON
Start date: December 13, 2022
Phase: Phase 2
Study type: Interventional

The primary objective of the FALCON study is to evaluate the efficacy of KL1333 on selected disease manifestations of primary mitochondrial disease (PMD) following 48 weeks of treatment. This objective involves evaluating the efficacy of KL1333 versus placebo on fatigue symptoms and impacts on daily living as well as on functional lower extremity strength and endurance. Additionally, the study evaluates the safety and tolerability of KL1333.

NCT ID: NCT05162768 Active, not recruiting - Clinical trials for Mitochondrial Diseases

Study to Evaluate Efficacy and Safety of Elamipretide in Subjects With Primary Mitochondrial Disease From Nuclear DNA Mutations (nPMD)

NuPower
Start date: April 29, 2022
Phase: Phase 3
Study type: Interventional

SPIMD-301 is a 48-week, randomized, double-blind, parallel-group, placebo-controlled trial to assess efficacy and safety of single daily subcutaneous (SC) administration of elamipretide as a treatment for subjects with primary mitochondrial myopathy associated with nuclear DNA mutations (nPMD).

NCT ID: NCT02920671 Active, not recruiting - Obesity Clinical Trials

Muscle OXPHOS and Nutrient Homeostasis

Start date: February 14, 2017
Phase:
Study type: Observational

Investigators are recruiting adults (men and women, ages 18 to 65 years, inclusive) with a confirmed genetic diagnosis of mitochondrial disease. Investigators are also recruiting both obese and normal-weight healthy volunteers (men and women, ages 18 to 65 years, inclusive) without a family history of mitochondrial disease to compare to affected individuals. The study involves non-invasive MRI methods and glucose tests to focus on the relationship between mitochondrial disease, obesity, and the risk of diabetes. All study visit procedures will be completed within 2 days, which includes an overnight stay at the Hospital of the University of Pennsylvania. There are no study medications or sedations, and participants will be continually monitored during minimally-invasive procedures (e.g., blood draws). All participants will be able to receive compensation. Furthermore, it may be possible to provide reimbursement for travel, lodging, and meals for individuals with mitochondrial disease. Investigators hope that this research will contribute to the current knowledge of mitochondrial disease and that it will improve diagnostic and treatment approaches.

NCT ID: NCT02000284 Active, not recruiting - Clinical trials for Autism Spectrum Disorder

Mitochondrial Dysfunction in Autism Spectrum Disorder

Mito
Start date: October 16, 2012
Phase:
Study type: Observational

Researchers at Arkansas Children's Hospital Research Institute are conducting a study about mitochondrial function in children. The study involves up to 5 visits to Arkansas Children's Hospital with fasting blood draws, behavioral assessments, and/or questionnaires. This study is not currently recruiting, but continues to follow those who were enrolled. There is no cost for visits or study-related exams. For further information, please contact the program manager, Leanna Delhey, at ldelhey@uams.edu or 501-364-4519